Adagene

ADAG Lead: Phase 2 8 Biotech Distilled articles ↓

Most recent annual filing: 2026-04-01

Catalyst timeline

ADG126 Ph2 startMid-2026ADG126 Ph2 start, Mid-2026, routine
ADG126 Ph3 start2027ADG126 Ph3 start, 2027, notable

Bar width shows how precise the guidance is — a pin is a stated date, a wide band a six-month window. Deeper blue means more of the thesis rides on the event; it is not a view on the stock.

Pipeline (10 active programs)

muzastotug

ADG126

Protein Target: CTLA-4

Colorectal Cancer Phase 2 intravenous Merck NCT06846268
Hepatocellular Carcinoma Phase 1 Roche
Solid Tumors Phase 1 Sanofi NCT04645069

Undisclosed indication Phase 2 Sanjin

ADG125

Protein Target: CSF-1R

Undisclosed indication Phase 2 Dragon Boat Biopharmaceuticals

ADG138

Protein Target: HER2, CD3

Undisclosed indication Preclinical

ADG153

Protein Target: CD47

Undisclosed indication Preclinical

ADG152

Protein Target: CD20, CD3

Undisclosed indication Preclinical

Technology platforms

DPL

Dynamic Precision Library (DPL) — computational biology-driven antibody discovery platform powering NEObody, SAFEbody, and POWERbody technologies for novel cancer immunotherapy development

NEObody

NEObody technology — antibody engineering platform targeting unique, evolutionarily conserved epitopes with species cross-reactivity; focus on oncology/immuno-oncology targets including CTLA-4 and CD137

SAFEbody · Sanofi

SAFEbody precision masking technology — proprietary platform that masks antibody binding sites for conditional activation in the tumor microenvironment, reducing on-target off-tumor toxicity; licensed to Sanofi and Exelixis for tumor targets

POWERbody

POWERbody technology — Fc-engineering and bispecific T-cell engager platform combining SAFEbody masking with enhanced effector function (IgG1 isotype and enhanced versions) for oncology; includes masked TCEs with co-stimulatory signals such as CD28

SAFEbody · Exelixis

Precision masking technology that shields the binding domain of antibody therapeutics, enabling tumor-specific activation in the tumor microenvironment while minimizing on-target off-tumor toxicity; applicable to Fc-empowered antibodies, ADCs, and bi/multi-specific T-cell engagers across oncology indications

Dynamic Precision Library

Proprietary platform composed of NEObody, SAFEbody, and POWERbody technologies; computational biology and AI-driven antibody discovery platform for novel cancer immunotherapies

Discontinued (1)

ADG106 — undisclosed · deprioritized

Biotech Distilled coverage (8)

2026-08-13 UPDATE: Adagene (ADAG) - The Answer to the $53M Question 🔒 Paid
2026-07-06 UPDATE: Adagene (ADAG) - The Dilution Gap Just Slammed Shut 🔒 Paid
2026-05-08 UPDATE: Adagene (ADAG) – The Coil Tightens 🔒 Paid
2026-03-21 UPDATE: Adagene (ADAG) – The Whales Keep Circling 🔒 Paid
2026-02-21 UPDATE: Adagene (ADAG) – The Whale That Sold to the Whale 🔒 Paid
2026-01-30 UPDATE: Adagene (ADAG) – Following the Smart Money 🔒 Paid
2026-01-25 UPDATE: Adagene (ADAG) – Did The Dilution Gap Just Close? 🔒 Paid
2026-01-02 Adagene Inc (ADAG): Scientific Due Diligence for Lead and Pipeline Products 🔒 Paid

Articles open on Substack. Some deep dives are subscriber-only.